What Is NAD+? Research Evidence & Profile

What Is NAD+?

NAD+ is the oxidized form of nicotinamide adenine dinucleotide, a central cofactor in redox biology. This page identifies the material as Nicotinamide Adenine Dinucleotide (NAD+), with synonyms NAD+, Nicotinamide Adenine Dinucleotide; physical form Coenzyme (not a peptide) - lyophilized powder. The NAD+ identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

This is a multi-component catalogue blend, so a single molecular formula, molecular weight or CAS number is not assigned to the combined product.

Evidence at a Glance

553ClinicalTrials.gov query records

17123PubMed query records

6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for NAD+ is organized around redox cofactor biology, enzyme and cofactor studies, metabolic-pathway research, and analytical compound characterization. For NAD+, those subjects define the literature and analytical context of this specific research compound; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
NCT02601157Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial	Phase 4	Completed	Stable Angina, Unstable Angina, Non-ST Segment Elevation Myocardial Infarction	2023-01-10
NCT05513807Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant	Phase 3	Completed	Delayed Graft Function	2024-07-10
NCT00128453Study of Colchicine to Treat Acute Pericarditis and Prevent Recurrences	Phase 3	Completed	Pericarditis	2012-06-07
NCT03865927GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis	Phase 2	Completed	Idiopathic Pulmonary Fibrosis	2026-05-11
NCT04488627Reliability of Ultrasound Examination of the Inferior Caval Vein	Not stated	Unknown	Transthoracic Echocardiography	2020-08-19
NCT05488483A Study of Tumor Imaging With Multispectral Optoacoustic Tomography	Not stated	Active Not Recruiting	Breast Cancer, Melanoma	2026-02-19

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Nicotinamide adenine dinucleotide metabolism: driving or counterbalancing inflammatory bowel disease?

FEBS letters · 2023 May

PMID 36310388

Selected PubMed record

Nicotinamide Adenine Dinucleotide Supplementation to Alleviate Heart Failure: A Mitochondrial Dysfunction Perspective.

Nutrients · 2025 May 29

PMID 40507126

Selected PubMed record

Nicotinamide adenine dinucleotide phosphate oxidase in pancreatic diseases: Mechanisms and future perspectives.

World journal of gastroenterology · 2024 Feb 7

PMID 38414585

Selected PubMed record

Nicotinamide Adenine Dinucleotide-Loaded Lubricated Hydrogel Microspheres with a Three-Pronged Approach Alleviate Age-Related Osteoarthritis.

ACS nano · 2025 May 13

PMID 40315404

Selected PubMed record

Nicotinamide adenine dinucleotide emerges as a therapeutic target in aging and ischemic conditions.

Biogerontology · 2019 Aug

PMID 30838484

Selected PubMed record

Nicotinamide adenine dinucleotide (NAD+): essential redox metabolite, co-substrate and an anti-cancer and anti-ageing therapeutic target.

Biochemical Society transactions · 2020 Jun 30

PMID 32573651

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: Nicotinamide Adenine Dinucleotide (NAD+)
Available Specifications: 100mg, 500mg, 1000mg
Pack Format: 10 Vials
CAS Number: 53-84-9
Molecular Formula: C21H27N7O14P2
Molecular Weight: 663.4 g/mol
Synonyms: NAD+, Nicotinamide Adenine Dinucleotide
Physical Form: Coenzyme (not a peptide) - lyophilized powder

This is a multi-component catalogue blend, so a single molecular formula, molecular weight or CAS number is not assigned to the combined product.

Source: PubChem CID 5892 · Product form must still be matched to the catalogue and batch record.

Research Tools for NAD+

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

NAD+ Research Summary

Identity

Nicotinamide Adenine Dinucleotide (NAD+); specifications: 100mg, 500mg, 1000mg. This is a multi-component catalogue blend, so a single molecular formula, molecular weight or CAS number is not assigned to the combined product.

Mechanism

Evidence

553 registry records and 17123 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

NAD+ is represented here by the catalogue identity Nicotinamide Adenine Dinucleotide (NAD+). This is a multi-component catalogue blend, so a single molecular formula, molecular weight or CAS number is not assigned to the combined product. The product record lists 100mg, 500mg, 1000mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for NAD+ is organized around redox cofactor biology, enzyme and cofactor studies, metabolic-pathway research, and analytical compound characterization. For NAD+, those subjects define the literature and analytical context of this specific research compound; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 553 ClinicalTrials.gov records and 17123 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

NAD+ FAQ

What is NAD+?

What research records are indexed for NAD+?

The synchronized query returned 553 ClinicalTrials.gov records and 17123 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is NAD+ FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.